Literature DB >> 8163691

Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.

K Leiper1, A Croll, N A Booth, N R Moore, T Sinclair, B Bennett.   

Abstract

AIMS: To identify the relative contribution of plasminogen activators, particularly tissue plasminogen activator (t-PA) and specific plasminogen activator inhibitors (PAI-1, PAI-2), to the fibrinolytic changes associated with various types of liver disease or severe chemical and physical damage to the liver.
METHODS: Platelet rich (PRP) and platelet poor plasma (PFP) from patients with alcoholic cirrhosis, primary biliary cirrhosis, hepatic malignancy, or paracetamol overdose, or who were undergoing partial hepatectomy or liver transplantation, were assayed for t-PA, PAI-1, t-PA-PAI-1 complex and PAI-2 antigen values using specific enzyme linked immunosorbent assays (ELISAs) developed in this laboratory.
RESULTS: Appreciable increases in the plasma concentration of t-PA, PAI-1, and t-PA-PAI-1 were seen in patients with alcoholic cirrhosis, primary biliary cirrhosis, and hepatic malignancy. Liver damage due to paracetamol overdose and partial hepatectomy both resulted in a striking increase in plasma PAI-1 concentration, although concentrations of t-PA and t-PA-PAI-1 complex were less affected. Concentrations of t-PA, PAI-1, and t-PA-PAI-1 complex returned to near normal values after successful liver transplantation in a patient with chronic active hepatitis. PAI-2 was also detected in several patients with chronic liver disorders.
CONCLUSIONS: Haemorrhage due to fibrinolytic bleeding is commonly associated with liver disease. The patients studied here all had appreciable increases in circulating t-PA antigen concentrations. This was associated with increased concentrations of PAI-1 antigen and t-PA-PAI-1 complex and the balance between activator and inhibitor did not result in systemic plasmin generation. Reduced PAI-1 activity in cirrhosis or a critical difference in the ratio of t-PA to PAI-1 concentrations may explain the enhanced plasminogen activator activity previously noted in cirrhosis but not metastatic disease. Reduced hepatic clearance of t-PA and t-PA-PAI-1 complex due to impaired liver function may account for increased concentrations of free and complexed t-PA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163691      PMCID: PMC501897          DOI: 10.1136/jcp.47.3.214

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  18 in total

1.  FIBRINOLYTIC ACTIVITY IN CIRRHOSIS OF THE LIVER.

Authors:  G PURCELL; L L PHILLIPS
Journal:  Surg Gynecol Obstet       Date:  1963-08

2.  ABNORMAL PLASMINOGEN-PLASMIN SYSTEM ACTIVITY (FIBRINOLYSIS) IN PATIENTS WITH HEPATIC CIRRHOSIS: ITS CAUSE AND CONSEQUENCES.

Authors:  A P FLETCHER; O BIEDERMAN; D MOORE; N ALKJAERSIG; S SHERRY
Journal:  J Clin Invest       Date:  1964-04       Impact factor: 14.808

3.  Antifibrinolytic activity in primary carcinoma of the liver.

Authors:  H C KWAAN; R LO; A J MCFADZEAN
Journal:  Clin Sci       Date:  1959-05       Impact factor: 6.124

4.  Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, pre-eclampsia and hydatidiform mole.

Authors:  A Reith; N A Booth; N R Moore; D J Cruickshank; B Bennett
Journal:  Br J Obstet Gynaecol       Date:  1993-04

5.  A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.

Authors:  F W Leebeek; C Kluft; E A Knot; M P de Maat; J H Wilson
Journal:  Gastroenterology       Date:  1991-11       Impact factor: 22.682

6.  Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.

Authors:  C Tran-Thang; J Fasel-Felley; G Pralong; J R Hofstetter; F Bachmann; E K Kruithof
Journal:  Thromb Haemost       Date:  1989-09-29       Impact factor: 5.249

7.  The receptor for tissue plasminogen activator (t-PA) in complex with its inhibitor, PAI-1, on human hepatocytes.

Authors:  L R Wing; B Bennett; N A Booth
Journal:  FEBS Lett       Date:  1991-01-14       Impact factor: 4.124

8.  Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system.

Authors:  L R Wing; G M Hawksworth; B Bennett; N A Booth
Journal:  J Lab Clin Med       Date:  1991-02

9.  Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis.

Authors:  K Huber; J C Kirchheimer; C Korninger; B R Binder
Journal:  Thromb Res       Date:  1991-06-01       Impact factor: 3.944

10.  The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination.

Authors:  B Bennett; N A Booth; A Croll; A A Dawson
Journal:  Br J Haematol       Date:  1989-04       Impact factor: 6.998

View more
  8 in total

1.  Specificity of binding of the low density lipoprotein receptor-related protein to different conformational states of the clade E serpins plasminogen activator inhibitor-1 and proteinase nexin-1.

Authors:  Jan K Jensen; Klavs Dolmer; Peter G W Gettins
Journal:  J Biol Chem       Date:  2009-05-13       Impact factor: 5.157

2.  Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases.

Authors:  P Fitch; B Bennett; N A Booth; A Croll; S W Ewen
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

3.  Osteopontin is an important mediator of alcoholic liver disease via hepatic stellate cell activation.

Authors:  Devanshi Seth; Alastair Duly; Paul C Kuo; Geoffrey W McCaughan; Paul S Haber
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

4.  Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis?

Authors:  Valeria Rossetto; Luca Spiezia; Marco Senzolo; Krissia Isabel Rodriguez-Castro; Sabrina Gavasso; Barry Woodhams; Paolo Simioni
Journal:  Intern Emerg Med       Date:  2013-03-17       Impact factor: 3.397

5.  Plasminogen activator inhibitor-1 limits liver injury and facilitates regeneration after acetaminophen overdose.

Authors:  Mary Lynn Bajt; Hui-Min Yan; Anwar Farhood; Hartmut Jaeschke
Journal:  Toxicol Sci       Date:  2008-05-09       Impact factor: 4.849

6.  Tissue-Type Plasminogen Activator-Inhibitor Complex as an Early Predictor of Septic Shock: A Retrospective, Single-Center Study.

Authors:  Lincui Zhong; Jianlin Dou; Qingwei Lin; Longping He; Qingbo Zeng; Jingchun Song
Journal:  Dis Markers       Date:  2022-04-04       Impact factor: 3.464

Review 7.  Cirrhosis and Coagulopathy: Mechanisms of Hemostasis Changes in Liver Failure and Their Management.

Authors:  Rabia Islam; Sumana Kundu; Surajkumar B Jha; Ana P Rivera; Gabriela Vanessa Flores Monar; Hamza Islam; Sri Madhurima Puttagunta; Ibrahim Sange
Journal:  Cureus       Date:  2022-04-03

Review 8.  The pathophysiology of thrombocytopenia in chronic liver disease.

Authors:  Oscar Mitchell; David M Feldman; Marla Diakow; Samuel H Sigal
Journal:  Hepat Med       Date:  2016-04-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.